“Role of Nasopharyngeal Reflux in the Etiology of Otitis Media with Effusion”September 8, 2017
“Voice Problems Among Laryngopharyngeal Reflux Patients Diagnosed with Oropharyngeal pH Monitoring”September 8, 2017
Vailati C, Mazzoleni G, Bondi S, Bussi M, Testoni PA, Passaretti S. J Voice. 2013;27(1):84-9.
OBJECTIVES: to evaluate the relationship between pathological oropharyngeal pH-monitoring and clinical response to a 3-month double dose PPI therapy in patients with GERD-related laryngeal symptoms.
RESULTS: 13 patients (72.2%) were considered responders; 9 patients (50.0%) had a pathological oropharyngeal pH-monitoring study. Groups of responder and non responder patients were comparable regarding to demographic aspects. All the patients with a positive Restech® study were responsive to PPI, and 5 out of 9 patients with a negative Restech® study were non responders, with this difference being statistically significant (p=0.03). Responder patients resulted also in a higher rate of oropharyngeal acid exposure, expressed as Ryan Score, both in orthostatic and in supine position, compared to non responders (49.74 and 9.64 vs 2.12 and 2.17, p<0.05). Mean RSI score before therapy was 16.6±3.1. Considering responder patients, RSI score dropped from 16.25±3.9 to 7.87±3.2 after PPI therapy (p<0.05), whereas a not statistically significant reduction was observed in non responder patients (17±3.2 to 10.4±3, p=0.13).
CONCLUSION: all patients with pathological oropharyngeal acid exposure assessed with the Restech® probe clinically responded to a 3 months course of double dose PPI therapy. In the light of these results, If confirmed by future larger studies, the Restech® evaluation could be proposed as a tool for a better stratification of patients with LPS before starting a long medical therapy, which is generally associated with low rates of treatment compliance.